EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC 4.0

Small Molecule Therapy for Inflammatory Bowel Disease: JAK Inhibitors and S1PR Modulators

Yu Kyung Jun, Hyuk Yoon iD

The Korean Journal of Gastroenterology · 25.08.2024 · 84 (2) · 51-64

DOI: 10.4166/kjg.2024.064 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift The Korean Journal of Gastroenterology, erschienen am 25.08.2024. Verfasst von Yu Kyung Jun und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, Korea. Hauptthemen laut MEDLINE: Inflammatory Bowel Diseases, Janus Kinase Inhibitors, Sphingosine 1 Phosphate Receptor Modulators. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 91 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Small molecules, including Janus kinase (JAK) inhibitors and sphingosine-1-phosphate receptor modulators (S1PRMs), are promising new treatments for inflammatory bowel disease (IBD). Small molecules exhibit more predictable pharmacokinetics than biologics, are less likely to induce immune responses, and can be administered orally. JAK inhibitors function by blocking the activity of JAK enzymes, which prevents the subsequent phosphorylation and activation of signal transducer and activator of transcription (STAT) proteins. Tofacitinib and filgotinib are approved for treating ulcerative colitis (UC), while upadacitinib is approved for UC and Crohn's disease. Nevertheless, JAK inhibitors can increase the risk of herpes zoster, cancer, major adverse cardiovascular events, and venous thromboembolism. S1PRMs bind to S1PRs, particularly S1PR1, on lymphocytes. This interaction inhibits lymphocytes from exiting the lymph nodes and migrating to the gut, thereby reducing inflammation and the immune response in the intestinal mucosa. Ozanimod and etrasimod are S1PRMs approved for the treatment of UC, but they can cause side effects such as bradycardia, conduction disorder, and macular edema. Overall, JAK inhibitors and S1PRMs offer significant benefits in managing IBD, although their potential side effects require careful monitoring.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Inflammatory Bowel DiseasesJanus Kinase InhibitorsSphingosine 1 Phosphate Receptor ModulatorsHumansIndansOxadiazolesPyridinesReceptors, LysosphingolipidSphingosine-1-Phosphate ReceptorsTriazoles

Stichwörter der Autor:innen

Inflammatory bowel diseasesJanus kinase inhibitorsSphingosine 1 phosphate receptor modulators

Substanzen

GLPG0634IndansJanus Kinase InhibitorsOxadiazolesozanimodPyridinesReceptors, LysosphingolipidSphingosine 1 Phosphate Receptor ModulatorsSphingosine-1-Phosphate ReceptorsTriazoles

Autor:innen und Institutionen

  • Department of Gastroenterology, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, Korea.

ORCID-Profile: Hyuk Yoon

Zitieren

APA

Jun, Y. K., & Yoon, H. (2024). Small Molecule Therapy for Inflammatory Bowel Disease: JAK Inhibitors and S1PR Modulators. The Korean Journal of Gastroenterology, 84(2), 51-64. https://doi.org/10.4166/kjg.2024.064

Vancouver

Jun YK, Yoon H. Small Molecule Therapy for Inflammatory Bowel Disease: JAK Inhibitors and S1PR Modulators. The Korean Journal of Gastroenterology. 2024;84(2):51-64. doi:10.4166/kjg.2024.064

BibTeX
@article{Jun2024,
  author = {Jun, Yu Kyung and Yoon, Hyuk},
  title = {Small Molecule Therapy for Inflammatory Bowel Disease: JAK Inhibitors and S1PR Modulators},
  journal = {The Korean Journal of Gastroenterology},
  year = {2024},
  volume = {84},
  number = {2},
  pages = {51--64},
  doi = {10.4166/kjg.2024.064}
}
Kostenlos starten →